Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sefaxersen in Geographic Atrophy Secondary to AMD
NCT03446144Phase 2Withdrawn
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of sefaxersen in geographic atrophy (GA), sponsored by Ionis Pharmaceuticals. Planned start Mar 2018; status: withdrawn.
02
Drugs
sefaxersen
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03446144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446144.